Baxter International (BAX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Indivi ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Insulet (PODD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-an ...

From a technical perspective, Baxter International (BAX) is looking like an interesting pick, as it just reached a key level of support. BAX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support ...

RomoloTavani Introduction: The focus of most of our articles is on generating reliable and sustainable income along with decent growth. We publish a monthly article on “5 Relatively Secure And Cheap Dividend Stocks” to highlight some of the best candidates each month. However, that list changes to some extent from month to month since it is based on a specific filtering method, and as the data changes, so does the list. Last week, we published an article on “7 Income Funds” for passive investors. Today' ...

Baxter International, Inc. (BAX) recently announced that it has entered into a definitive agreement to divest its Vantive Kidney Care segment to Carlyle, a global investment firm, for $3.8 billion.In January 2023, Baxter announced its intention to create a standalone kidney care company intended to improve future performance and create value for all stakeholders. In March 2024, Baxter announced that it was in discussions to explore a potential sale of the Kidney Care segment.Following an analysis of the fin ...

Key TakeawaysBaxter shares slid after the company agreed to sell its kidney care division to Carlyle for $3.8 billion in cash.The company plans to use the roughly $3 billion in after-tax proceeds to reduce its debt.Carlyle's investment is being made through a partnership with Atmas Health. Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash. The deal is expected to generate roughly $3 billion ...

Pitchayanan Kongkaew/iStock via Getty Images Introduction 10 months ago, we had advised investors not to get too myopic about the consequences of the early termination of Novo Nordisk’s (NVO) kidney outcome FLOW trial on Baxter International (NYSE:BAX), but rather focus on some of the more favorable tailwinds surrounding the latter. The BAX stock has since continued to coast along just fine and gauging some of the key highlights from the Q2 results which came out yesterday, we feel even more enthused abo ...

Baxter International Inc. (BAX) reported second-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 68 cents, which beat the Zacks Consensus Estimate of 66 cents by 3%. The bottom line improved 23.6% from the year-ago quarter’s level.On a GAAP basis, the company reported a loss per share of 62 cents from continuing operations compared with a loss of 39 cents in the prior-year quarter.Continuing operations exclude Baxter's BioPharma Solutions business, which was divested during the t ...

Baxter International Inc. (NYSE:BAX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Securities David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Danielle Antalffy - UBS Mat ...